1FW



PATENT

Attorney Docket No.: UBC1180-2

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Hancock et al.

Art Unit:

1614

Application No.:

10/661,471

Examiner:

Not Yet Assigned

Filed:

September 12, 2003

Conf. No.:

7167

Title:

EFFECTORS OF INNATE IMMUNITY DETERMINATION

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) Information Disclosure Statement (2 pgs.);
- (2) PTO Form 1449 (2 pgs.);
- (3) Fifteen (15) References;
- (4) International Search Report (14 pgs.); and
- (5) Return postcard.

**CERTIFICATION UNDER 37 CFR §1.8** 

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on September 10, 2004, in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450

isa E. Jambeau

In re Application of: Hancock et al.

Application No.: 10.

Application No.: 10/661,471 Filed: September 12, 2003

Page 2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated June 11, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

PATENT

Attorney Docket No.: UBC1180-2

Date: September 10, 2004

Lisa A. Haile, J.D. Ph.D.

Registration No. 38,347 Telephone: (858) 677-1456 Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 USPTO Customer No. 28213



**PATENT** 

Attorney Docket No.: UBC1180-2

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Hancock et al.

Art Unit:

1614

Application No.:

10/661,471

Examiner:

Not Yet Assigned

Filed:

September 12, 2003

Conf. No.:

7167

Title:

EFFECTORS OF INNATE IMMUNITY DETERMINATION

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### **INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Additional references, not cited on the communication, have also been included. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

**CERTIFICATION UNDER 37 CFR §1.8** 

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on September 10, 2004, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandfia, VA 22313-1450.

Lisa E. Jambeau

In re Application of:

Hancock et al.

Application No.: 10/661,471 Filed: September 12, 2003

Page 2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated June 11, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

PATENT

Attorney Docket No.: UBC1180-2

Date: September 10, 2004

Lisa A. Haile, J.D., Ph.D. Registration No.: 38,347 Telephone: (858) 677-1456 Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 USPTO Customer Number 28213

Docket No. UBC1180-2			
Applicant: Hancock et al.	,		
Filing Date: September 12,2003	Group Art Unit: 1614		
	UBC1180-2  Applicant: Hancock et al.  Filing Date:		

# U.S. PATENT DOCUMENTS

EXAM. INITIALS		BOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	6,040,435A	03/21/2000	Karunarante et al.			

#### **FOREIGN PATENT DOCUMENTS**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	AB	WO0012528A	03/09/2000	Canada			No

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

AC	Scott MG. et al., "An alpha-Helical Cationic Antimicrobial Peptide Selectively Modulates Macrophage Responses to Lipopolysaccharide and Directly Alters Macrophage Gene Expression", <i>The Journal of Immunology</i> , Vol. 165, 3358-3365, 2000
AD	Scott, MG. et al., "Biological Properities of Structurally Related alpha-Helical Cationic Antimicrobial Peptides", <i>Infection and Immunity</i> , Vol. 67, No. 4, 2005-2009, April 1999 (1999-04)
AE	Hancock R.E. et al., "The role of antimicrobial peptides in animal defense", Proceedings of The National Academy of Sciences of The United States of America, Vol. 97, No. 16, 8856-8861, August 1, 2000
AF	Luftfalla, G. et al., "Mutant U5A cells are complemented by an interferon-alpha beta receptors subunit generated by alternative processing of a new member of a cytokine receptor gene cluster", <a href="http://www.ncbi.nlm">http://www.ncbi.nlm</a> , accession no. L042243, April 4, 1996
AG	Mishima, K. et al., "ARD1, a 64-kDa guanine nucleotide-binding protein with a carboxyl-terminal ADP-ribosylation factor domain", <a href="http://www.ncbi.nlm">http://www.ncbi.nlm</a> , accession no. L04510, June 12, 1993

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of commerce Paters and	Docket No. UBC1180-2	Serial No.: 10/661,471
Trademark Office	Applicant: Hancock et al.	
INFORMATION DISCERNATION BY APPLICANT	Filing Date: September 12,2003	Group Art Unit: 1614

АН	Van Wetering, S., "Defensins: Key Players or Bystanders in Infection, Injury, and Repair in the Lungs?", <i>Journal of Allergy and Clinical Immunology</i> , Mosby-Yearlybook, Inc., US, Vol. 104, No. 6, 1131-1138, 1999
AI	Doranz, B.J. et al., "A Small-Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Corecptor", <i>Journal of Experimental Medicine, Tokyo, JP</i> , Vol. 186, No. 8, 1395-1400, October 20, 1997
AJ	Sareneva, T. et al., "Ifn-α and IL-12 Induce IL-18 Receptor Gene Expression in Human NK and T Cells," <i>The Journal Of Immunology</i> , Vol. 165: 1993-1938, 2000
AK	Wu, H. et al. "Regulation of Cathelicidin Gene Expression: Induction by Lipopolysacchride, interleukin-6, Retinoic Acid, and Salmonella enterica Serovar Typhimurium Infection", Infection and Immunity, 5552-5558, 2000
AL	Scott, M.G. et al., "Cationic Antimicrobial Peptide and Their Multifunctional Role in the Immune System", Critical Review in Immunology, CRC Press, Vol. 20, 407-431, 2000
AM	Hancock, R.E. and Lehrer, R., "Cationic peptides: a new source of antibiotics", <i>Trends in Biology, Elsevier Publication</i> , Vol. 16, No. 2, February 1, 1998
AN	Hancock, R.E., "Catitonic peptides:effectors in innate immunity and novel antimicrobials", The Lancet Infectious Diseases, Vol. 1 No. 3, 156-164, October 2001
AO	Mcquibban, G.A. et al., "Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1", <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 47, November 23, 2001

EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.